IPH-6101 is under clinical development by Innate Pharma and currently in Phase II for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase II drugs for Relapsed Acute Myeloid Leukemia have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IPH-6101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
IPH-6101 overview
IPH-6101 is under development for the treatment of acute myelocytic leukemia (AML), relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), blastic plasmacytoid dendritic cell neoplasm (BPDCN) and high risk-myelodysplasia (HR-MDS). The tri-specific antibody NKp46/CD16-based NK cell engager that targets CD123. NKp46 is a NK cell specific surface molecule of 46 kD (p46) that is expressed by all resting or activated NK cells. It is administered through intravenous route. It is being developed based on ANKET platform.
It was also under development for the treatment of inflammation.
Innate Pharma overview
Innate Pharma is a clinical-stage biotechnology company that develops immunotherapies for cancer patients. Its pipeline products include lacutamab which treats cutaneous t cell lymphoma and peripheral t cell lymphoma; monalizumab treats unresectable stage III non-small cell lung cancer; IPH5201 for neoadjuvant non-small cell lung cancer; IPH5301 which treats cancer (solid tumors); IPH6101 for acute myeloid leukemia, b-cell acute lymphoblastic leukemia, high risk-myelodysplasia; IPH6401 treats multiple myeloma; IPH62, IPH67, IPH6501 which treats cancer and pre clinical products comprise IPH45, IPH43. The company uses ANKET (Antibody-based NK cell Engager Therapeutics) a proprietary platform to develop multi-specific NK cell engagers to treat certain types of cancer. It collaborates with biopharmaceutical companies and research institutions to develop its products. Innate Pharma is headquartered in Marseille, France.
For a complete picture of IPH-6101’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
